Haier Biomedical reports higher first-half revenue and profit, with emerging businesses accelerating

证券日报··CNGBSG·Read original
2▲3 ▼0Impact / 5
Summary · why it matters

Haier Biomedical has released its 2026 interim report. First-half operating revenue reached a record high of 1.296 billion yuan, up 8.45 percent year on year, while net profit attributable to the parent company was 147 million yuan, up 3.28 percent. Both revenue and profit growth in the second quarter were faster than in the first quarter. Pharmaceutical customers were the main driver of revenue growth, with related revenue up 23 percent in the first half. Domestically, the company deepened cooperation with leading pharmaceutical firms including WuXi Biologics, GenSci, Pien Tze Huang and Qilu Pharmaceutical. Overseas, it newly entered research and production bases in countries such as the United Kingdom and Singapore, and has now served nearly half of the world's top 25 pharmaceutical companies. Growth continued in major global markets, with the European Union, the United Kingdom and the United States together rising 17 percent. Smart medication solutions expanded rapidly into 10 countries including Thailand, Vietnam, Malaysia, Morocco and Saudi Arabia. The low-temperature business grew 13 percent year on year, achieving positive growth for four consecutive quarters. The laboratory solutions business grew 19 percent, and the smart medication business grew 11 percent. Revenue from AI-related businesses rose to 18 percent of total revenue, up 3 percentage points from 2025. The company expects both revenue and profit growth to accelerate in the second half, with full-year profit growth broadly matching revenue growth.

Impact on assets 3

Biotech & Genomic Medicine▲ · 1 stocks
WuXi Biologics
2269
▲ PositiveDemandrelevance

Deepened cooperation with Haier Biomedical, driving pharmaceutical revenue growth.

Others▲ · 2 stocks

Off-coverage companies 2

Changchun GeneScience Pharmaceutical Co., Ltd.Private▲ Positive
Demandrelevance

Deepened cooperation with Haier Biomedical, driving pharmaceutical revenue growth.

齐鲁制药Private▲ Positive
Demandrelevance

Deepened cooperation with Haier Biomedical, driving pharmaceutical revenue growth.

© 2026 MarketIVNews